These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23702810)

  • 21. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
    Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
    Hibi T; Hirohata S; Kikuchi H; Tateishi U; Sato N; Ozaki K; Kondo K; Ishigatsubo Y
    Medicine (Baltimore); 2016 Jun; 95(24):e3863. PubMed ID: 27310969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.
    Katz L; Gisbert JP; Manoogian B; Lin K; Steenholdt C; Mantzaris GJ; Atreja A; Ron Y; Swaminath A; Shah S; Hart A; Lakatos PL; Ellul P; Israeli E; Svendsen MN; van der Woude CJ; Katsanos KH; Yun L; Tsianos EV; Nathan T; Abreu M; Dotan I; Lashner B; Brynskov J; Terdiman JP; Higgins PD; Chaparro M; Ben-Horin S
    Inflamm Bowel Dis; 2012 Nov; 18(11):2026-33. PubMed ID: 22294554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
    Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
    Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
    Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
    Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term infliximab treatment for Behçet's disease.
    Takamoto M; Kaburaki T; Numaga J; Fujino Y; Kawashima H
    Jpn J Ophthalmol; 2007; 51(3):239-40. PubMed ID: 17554493
    [No Abstract]   [Full Text] [Related]  

  • 28. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
    Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
    Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J; Ji DN; Shen Y; Guan JL; Zheng SB
    Ann Clin Lab Sci; 2017 Mar; 47(2):171-177. PubMed ID: 28442519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
    Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
    Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH; Kim HS; Han DS; Kim SK; Shin SJ; Kim JS; Ye BD; Song GA; Lee Y; Kim Y; Lee Y; Kim WH;
    Gut Liver; 2023 Sep; 17(5):777-785. PubMed ID: 36578194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
    Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J; Shin SJ; Park YJ; Kim HW; Lee BI; Ye BD; Kim GT; Kim SK; Kim JS; Kim YH; Jeong S; Cheon JH
    BMC Gastroenterol; 2023 Dec; 23(1):449. PubMed ID: 38114956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.
    Park J; Park SJ; Park JJ; Kim TI; Cheon JH
    J Gastroenterol Hepatol; 2023 Mar; 38(3):386-392. PubMed ID: 36346041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease.
    Elezoglou A; Kafasi N; Kaklamanis PH; Theodossiadis PG; Kapsimali V; Choremi E; Vaiopoulos G; Sfikakis PP
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S65-9. PubMed ID: 17949554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL; Sipponen T
    Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab for patients with neuro-Behcet's disease: case series and literature review.
    Borhani Haghighi A; Safari A; Nazarinia MA; Habibagahi Z; Shenavandeh S
    Clin Rheumatol; 2011 Jul; 30(7):1007-12. PubMed ID: 21431864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.